retention rates comparable for biosimilars, original drug in spondyloarthritis
Published 5 years ago • 48 plays • Length 4:52Download video MP4
Download video MP3
Similar videos
-
19:32
understanding biosimilars
-
2:02
biosimilars show promise and progress
-
28:10
breaking down biosimilars: icymi
-
4:42
biosimilars vs. biologics: side effects, safety and effectiveness
-
3:33
biosimilars: manufacturing and inherent variation
-
38:15
biosimilars and biologics
-
5:49
i cured my ankylosing spondylitis
-
6:25
does every ankylosing spondylitis warrior require biologic therapy?
-
1:27:27
spondyloarthritis treatment and research updates with rheumatologist joerg ermann, md.
-
3:29
tnf inhibitors for ankylosing spondylitis
-
4:20
fda approves biosimilar to humira – ibd in the news
-
7:21
biologic drugs and biosimilars
-
2:31
abatacept equaled adalimumab for rheumatoid arthritis
-
6:18
fda approves of biosimilar to infliximab – ibd in the news
-
6:00
filgrastim vs filgrastim biosimilars for prevention of febrile neutropenia
-
2:25
dr. diane lacaille - biologics and biosimilars: are they equally effective and safe?
-
3:00
tnf inhibitors limit ra progression
-
57:53
biosimilars: what you need to know
-
3:09
biosimilars vs. generic drugs
-
34:22
pinpointing the top questions and considerations about biosimilars in rheumatology
-
14:19
regulatory pathway for biosimilars